SCHEDULE 13G/A: Millennium Entities Update Passive Stake in Puma Biotechnology

Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, updating their passive beneficial ownership in Puma Biotechnology, Inc. as of December 31, 2024.

Summary

• The filing is an Amendment No. 3 to a Schedule 13G, reporting beneficial ownership of Common Stock, par value $0.0001 per share, of Puma Biotechnology, Inc. (CUSIP: 74587V107).
• The reporting persons are Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, who are filing as a group.
• As of December 31, 2024, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially own 1,894,126 shares, representing 3.9% of the class.
• Integrated Core Strategies (US) LLC beneficially owns 1,388,298 shares, representing 2.8% of the class.
• All reporting persons disclaim any intent to change or influence the control of Puma Biotechnology, Inc.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing passive beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Puma Biotechnology, Inc.'s future performance or operations.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by reporting persons)

Industry Context

This filing is a routine disclosure of institutional ownership, indicating continued passive investment interest in Puma Biotechnology, Inc. by Millennium Management and its affiliates. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, confirming a passive investment stance by Millennium entities.

Key Dates

Keywords

Puma Biotechnology, PBYI, Schedule 13G/A, beneficial ownership, institutional investor, Millennium Management LLC, Integrated Core Strategies (US) LLC, Israel A. Englander, passive investment